What is the survival rate for Lung Cancer by stage

Lung Cancer Survival Rates by Stage

I'll help you understand survival rates for lung cancer. It's important to know that these are general statistics — your individual situation depends on many factors your doctor will discuss with you.

Overall Lung Cancer Survival

According to the NCCN Guidelines, the overall 5-year relative survival rate for all lung cancers combined is approximately 25.4%. However, this varies significantly by stage and type.

For adenocarcinoma (the most common type of lung cancer), the 5-year survival rate is 32.2%.

Survival Rates by Stage

Survival rates improve dramatically with earlier detection:

Early-Stage Disease (Stages 1-3):

• Patients with early and locally advanced NSCLC who receive appropriate treatment (surgery, radiation, or chemoradiation) have substantially better outcomes than advanced disease
• The NCCN Guidelines note that survival rates have improved significantly in recent years

Advanced/Metastatic Disease (Stage 4):

• Patients with advanced NSCLC who receive targeted therapies or immunotherapies based on their biomarkers are surviving longer
• 5-year survival rates now range from 15% to 62.5%, depending on the biomarker (such as EGFR mutations, ALK rearrangements, or PD-L1 expression)
• This represents a major improvement compared to historical data

Why Biomarker Testing Matters

According to NCCN Guidelines, biomarker testing is critical because it guides treatment selection. Patients with specific mutations or biomarkers may qualify for targeted therapies that significantly extend survival compared to chemotherapy alone.

Important Context

These statistics represent population averages and don't predict individual outcomes. Your survival depends on:

• Your specific cancer stage and type
• Biomarker results (EGFR, ALK, PD-L1, etc.)
• Your overall health and lung function
• Which treatments you receive
• How your cancer responds to treatment

Questions to Ask Your Oncologist

1. What is my specific cancer stage and type?
2. What are my biomarker results, and what do they mean for my treatment options?
3. Based on my individual situation, what survival statistics are most relevant to me?
4. What factors in my case might affect my prognosis?
5. Are there clinical trials available for my stage and biomarker profile?

---

Sources:

• NCCN Guidelines for Non-Small Cell Lung Cancer (Version 8.2025)
• NCCN Guidelines for Patients: Early and Locally Advanced Non-Small Cell Lung Cancer (2024)
• NCCN Guidelines for Patients: Metastatic Non-Small Cell Lung Cancer

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.